The COLchicine Cardiovascular Outcomes Trial (COLCOT) is the study of the Pharmacogenomics of the Efficacy and Safety of Colchicine (doi: 10.1161/CIRCGEN.120.003183). The PheWeb instance associated to this project is available at https://statgen.org/pheweb/colcot/.
A genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial was performed (doi: 10.1038/s41598-021-90365-6). The PheWeb instance associated to this project is available at https://statgen.org/pheweb/colcorona/.
The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomised, double-blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorised according to left ventricular ejection fraction and tolerability to an ACE inhibitor. We conducted a pharmacogenomic study of the CHARM studies to identify genetic predictors of heart failure progression and the efficacy and safety of treatment with candesartan (doi: 10.1002/ehf2.14026). The PheWeb instance associated to this project is available at https://pheweb.statgen.org/charm/.